Blood Res.  2020 Sep;55(3):151-158. 10.5045/br.2020.2020056.

Drug use evaluation of opioid analgesics in pain management among patients with hematopoietic stem cell transplantation

• Oh HJ
• Hong SY
• Jeong YM
• Choi KS
• Lee E
• Lee E
• Kim YJ
• Bang SM

• KMID: 2507055
• DOI: http://doi.org/10.5045/br.2020.2020056

Abstract

Background
Hematopoietic stem cell transplantation (HSCT) patients usually experience mucositis, musculoskeletal pain associated with high-dose chemotherapy, radiation, post-HSCT infection, or graft-versus-host disease. Pain management is important for the patients’ quality of life. We evaluated appropriate opioid analgesic use in HSCT patients to propose effective pain management strategies.
Methods
A retrospective analysis was conducted using electronic medical records of adult patients with HSCT treated with opioids for moderate to severe pain at Seoul National University Bundang Hospital. The numeric rating scale (NRS) was used in pain management. NRS scores of 4‒10 correspond to moderate to severe pain. Appropriate opioid analgesic use was evaluated following published cancer pain management guidelines.
Results
In total, 119 cases were evaluated, including 369 episodes of moderate to severe pain. Mucositis-related, musculoskeletal, and headache pain occurred in 62.6%, 25.8%, and 6.0% of episodes, respectively. Frequently used opioids were intravenous tramadol (84.9%), fentanyl patch (73.9%), and intravenous morphine sulfate (68.9%). Intravenous and topical administrations were used for mucosal pain. In total, 95.0% of patients received appropriate short-acting opioids for initial pain management, 80.5% received appropriate doses of short-acting opioids, appropriate opioids dose adjustment was done after first assessment in 95.5% of patients, and 85.6% were converted to appropriate long-acting opioids.
Conclusion
Short-acting opioid analgesic use for initial pain management and dose adjustment after assessment were appropriate. However, initial and conversion dosages recommended by guidelines may be difficult to implement considering the severity of HSCT patients. Pain management guidelines specific for HSCT patients should be developed in the future.

Keyword

Hematopoietic stem cell transplantation; Opioid; Analgesics; Pain management

Reference

1. National Cancer Institute. 2018. NCI dictionary cancer terms: hematologic cancer. National Cancer Institute;Bethesda, MD: at https://www.cancer.gov/publications/dictionaries/cancer-terms/def/hematologic-cancer. Accessed June 10, 2018.

2. Korean Statistical Information Service. 2019. 5 years prevalence number and relative frequency of 61 cancer types (2017). Statistics Korea;Daejeon, Korea: at http://kosis.kr/statHtml/statHtml.do?orgId=117&tblId=DT_117N_A00121&conn_path=I2. Accessed May 30, 2019.

3. Lee JJ, Ahn JS. 2010; Recently increasing hematologic diseases in Korea. Korean J Med. 78:557–63. DOI: 10.3343/alm.2019.39.2.133.

4. Hatzimichael E, Tuthill M. 2010; Hematopoietic stem cell trans-plantation. Stem Cells Cloning. 3:105–17. DOI: 10.2147/SCCAA.S6815.

5. Gyurkocza B, Sandmaier BM. 2014; Conditioning regimens for hematopoietic cell transplantation: one size does not fit all. Blood. 124:344–53. DOI: 10.1182/blood-2014-02-514778.

6. Larsen J, Nordström G, Ljungman P, Gardulf A. 2004; Symptom occurrence, symptom intensity, and symptom distress in patients undergoing high-dose chemotherapy with stem-cell trans-plantation. Cancer Nurs. 27:55–64. DOI: 10.1097/00002820-200401000-00007. PMID: 15108952.

7. Anderson KO, Giralt SA, Mendoza TR, et al. 2007; Symptom burden in patients undergoing autologous stem-cell transplantation. Bone Marrow Transplant. 39:759–66. DOI: 10.1038/sj.bmt.1705664. PMID: 17438588.

8. Niscola P, Arcuri E, Giovannini M, et al. 2004; Pain syndromes in haematological malignancies: an overview. Hematol J. 5:293–303. DOI: 10.1038/sj.thj.6200530. PMID: 15297845.

9. Martino M, Morabito F, Console G, et al. 2003; Differences in transplant-related complications between hematologic malignancies and solid tumors receiving high-dose chemotherapy and autologous peripheral blood stem cell transplantation. Tumori. 89:385–90. DOI: 10.1177/030089160308900407. PMID: 14606640.

10. Chapko MK, Syrjala KL, Schilter L, Cummings C, Sullivan KM. 1989; Chemoradiotherapy toxicity during bone marrow transplantation: time course and variation in pain and nausea. Bone Marrow Transplant. 4:181–6. PMID: 2650788.

11. Niscola P, Romani C, Cupelli L, et al. 2007; Mucositis in patients with hematologic malignancies: an overview. Haematologica. 92:222–31. DOI: 10.3324/haematol.10232. PMID: 17296572.

12. Bassi S, Stroppa EM, Moroni CF, et al. 2015; Safety and efficacy of granulocyte colony-stimulating factor biosimilars in engraftment after autologous stem cell transplantation for haematological malignancies: a 4-year, single institute experience with different conditioning regimens. Blood Transfus. 13:478–83. DOI: 10.2450/2015.0198-14. PMID: 25761321. PMCID: PMC4614302.

13. Cohen MZ, Rozmus CL, Mendoza TR, et al. 2012; Symptoms and quality of life in diverse patients undergoing hematopoietic stem cell transplantation. J Pain Symptom Manage. 44:168–80. DOI: 10.1016/j.jpainsymman.2011.08.011. PMID: 22699091. PMCID: PMC4270122.

14. Haverman TM, Raber-Durlacher JE, Rademacher WMH, et al. 2014; Oral complications in hematopoietic stem cell recipients: the role of inflammation. Mediators Inflamm. 2014:378281. DOI: 10.1155/2014/378281. PMID: 24817792. PMCID: PMC4003795.

15. Park JM. Korean Society of Anesthesiologists. 2010. Cancer pain. Anesthesiology and pain medicine. Ryo Moon Gak;Seoul, Korea: p. 379–98.

16. Paice JA, Ferrell B. 2011; The management of cancer pain. CA Cancer J Clin. 61:157–82. DOI: 10.3322/caac.20112. PMID: 21543825.

17. Wardley AM, Jayson GC, Swindell R, et al. 2000; Prospective evaluation of oral mucositis in patients receiving myeloablative conditioning regimens and haemopoietic progenitor rescue. Br J Haematol. 110:292–9. DOI: 10.1046/j.1365-2141.2000.02202.x. PMID: 10971384.

18. National Cancer Center. 2018. Cancer pain management guideline. 6th ed. National Cancer Center;Goyang, Korea: at https://www.cancer.go.kr/docview/preview.do?uuid=718e6e53-b442-471e-b884-b49724a4a011.pdf. Accessed June 1, 2018.

19. National Comprehensive Cancer Network. 2018. Clinical Practice Guidelines in Oncology: adult cancer pain. Version 1 (2018). National Comprehensive Cancer Network;Plymouth Meeting, PA: at https://www.nccn.org/professionals/physician_gls/default.aspx#pain. Accessed June 1, 2018.

20. Gabriel DA, Shea T, Olajida O, Serody JS, Comeau T. 2003; The effect of oral mucositis on morbidity and mortality in bone marrow transplant. Semin Oncol. 30(6 Supp1 18):76–83. DOI: 10.1053/j.seminoncol.2003.11.040. PMID: 14727245.

21. Park SM, Han SH, Yoo SH, Lee YH, Lee HS, Oh JM. 2012; Evaluation of the adequacy of pain control using opioid analgesics in palliative ward patients using Cancer Pain Management Guidelines. J Kor Soc Health-Syst Pharm. 29:281–7. DOI: 10.32429/jkshp.2012.29.3.005.

22. Kim HT, Koh KW, Kim YM, et al. 2009; Pain management based on NCCN Guideline in patients with lung cancer. Tuberc Respir Dis. 67:221–5. DOI: 10.4046/trd.2009.67.3.221.

23. Ministry of Food and Drug Safety. 2018. Medicines patent information: tramadol hydrochloride. Ministry of Food and Drug Safety;Cheongju, Korea: at https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetail?itemSeq=198500825. Accessed January 28, 2019.

24. Park SS. 2010; Cancer pain management - opioids. J Korean Med Assoc. 53:250–7. DOI: 10.5124/jkma.2010.53.3.250.

25. Lehmann KA. 1994; Tramadol for the management of acute pain. Drugs. 47(Suppl 1):19–32. DOI: 10.2165/00003495-199400471-00005.

26. Xing SZ, Zhang Y. 2015; Efficacy and safety of transdermal fentanyl for the treatment of oral mucositis pain caused by chemoradiotherapy in patients with esophageal squamous cell carcinoma. Support Care Cancer. 23:753–9. DOI: 10.1007/s00520-014-2419-5.

27. Guo SP, Wu SG, Zhou J, et al. 2014; Transdermal fentanyl for pain due to chemoradiotherapy-induced oral mucositis in nasopharyngeal cancer patients: evaluating efficacy, safety, and improvement in quality of life. Drug Des Devel Ther. 8:497–503. DOI: 10.2147/DDDT.S60187. PMID: 24872680. PMCID: PMC4026399.

28. Kress HG. 2009; Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine. Eur J Pain. 13:219–30. DOI: 10.1016/j.ejpain.2008.04.011. PMID: 18567516.

29. Electronic Medicines Compendium. 2018. Summary of product characteristics: buprenorphine. Datapharm Communications Limited;Leatherhead, UK: at https://www.medicines.org.uk/emc/product/9797/smpc. Accessed January 28, 2019.

30. Ministry of Food and Drug Safety. 2018. Medicines patent information: buprenorphine. Ministry of Food and Drug Safety;Cheongju, Korea: at https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetail?itemSeq=200410877. Accessed January 28, 2019.